MediWound is a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Its strategy is centered around its validated enzymatic platform technology, focused on next-generation bio-active therapies for burn and wound care and biological medicinal products for tissue repair.
Company profile
Ticker
MDWD
Exchange
Website
CEO
Sharon Malka
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
MDWD stock data
Analyst ratings and price targets
Current price
Average target
$34.00
Low target
$23.00
High target
$63.00
HC Wainwright & Co.
Maintains
$23.00
Cowen & Co.
Maintains
$25.00
Maxim Group
Initiated
$25.00
Oppenheimer
Maintains
$63.00
Latest filings (excl ownership)
424B3
Prospectus supplement
9 Jan 23
6-K
Current report (foreign)
9 Jan 23
424B3
Prospectus supplement
6 Jan 23
6-K
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
29 Dec 22
6-K
Current report (foreign)
23 Dec 22
6-K
Current report (foreign)
20 Dec 22
6-K
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005
19 Dec 22
6-K
MediWound Announces a 1-for-7 Reverse Share Split
5 Dec 22
6-K
Current report (foreign)
28 Nov 22
EFFECT
Notice of effectiveness
28 Nov 22
Transcripts
MDWD
Earnings call transcript
2022 Q3
15 Nov 22
MDWD
Earnings call transcript
2022 Q2
10 Aug 22
MDWD
Earnings call transcript
2022 Q1
17 May 22
MDWD
Earnings call transcript
2021 Q4
17 Mar 22
MDWD
Earnings call transcript
2021 Q3
16 Nov 21
MDWD
Earnings call transcript
2021 Q2
10 Aug 21
MDWD
Earnings call transcript
2020 Q4
28 Feb 21
MDWD
Earnings call transcript
2020 Q3
10 Nov 20
Latest ownership filings
SC 13G
Rosalind Advisors, Inc.
21 Dec 22
SC 13G
Deep Insight Limited Partnership
5 Dec 22
SC 13G
Israel Biotech Fund II, L.P.
5 Dec 22
SC 13D/A
Access Industries Holdings LLC
26 Sep 22
SC 13D/A
Access Industries Holdings LLC
1 Jul 22
SC 13D
Access Industries Holdings LLC
17 Mar 22
SC 13G/A
ROSENBERG LIOR
14 Feb 22
SC 13G
Migdal Insurance & Financial Holdings Ltd.
2 Feb 22
SC 13G
Migdal Insurance & Financial Holdings Ltd.
16 Feb 21
SC 13G/A
ROSENBERG LIOR
2 Feb 21
Financial summary
| Quarter (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q3 2022
52.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 30 |
| Opened positions | 8 |
| Closed positions | 1 |
| Increased positions | 5 |
| Reduced positions | 10 |
| 13F shares | Current |
|---|---|
| Total value | 35.42 mm |
| Total shares | 21.43 mm |
| Total puts | 21.30 k |
| Total calls | 0.00 |
| Total put/call ratio | Infinity |
| Largest owners | Shares | Value |
|---|---|---|
| Access Industries | 10.99 mm | $19.23 mm |
| Armistice Capital | 1.92 mm | $2.66 mm |
| Rosenberg Lior | 1.71 mm | $4.04 mm |
| DAFNA Capital Management | 1.43 mm | $1.99 mm |
| Altium Capital Management | 1.28 mm | $1.78 mm |
| WFC Wells Fargo & Co. | 795.29 k | $1.11 mm |
| Uniplan Investment Counsel | 714.25 k | $992.00 k |
| Sphera Funds Management | 688.72 k | $958.00 k |
| Sargent Investment | 562.35 k | $799.00 k |
| Renaissance Technologies | 427.04 k | $594.00 k |
News
Starbucks To Rally 11%? Here Are 10 Other Analyst Forecasts For Wednesday
4 Jan 23
HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $23
4 Jan 23
Cowen & Co. Maintains Outperform Rating for MediWound: Here's What You Need To Know
30 Dec 22
Cowen & Co. Maintains Outperform on MediWound, Adjusts Price Target to $25 - 1-for-7 Reverse Stock Split
30 Dec 22
FDA Approves MediWound's NexoBrid For Burn Treatment
30 Dec 22
Press releases
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
29 Dec 22
MediWound Expands NexoBrid's Global Presence with Marketing Approval in Japan
23 Dec 22
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
19 Dec 22
MediWound Expands Global Presence as NexoBrid® Gains Approval in India
13 Dec 22
MediWound Announces a 1-for-7 Reverse Share Split
5 Dec 22